Prime Medicine, Inc. (PRME) Stock Price & How to Invest

Prime Medicine is a gene-editing company developing therapies based on prime editing, a technology that pairs a CRISPR-derived nickase with a reverse transcriptase to make targeted search-and-replace edits to DNA without cutting both strands. The platform is positioned to address a broad range of genetic mutations and to deliver one-time treatments, but as of 2026 the company has no approved products and no product revenue. Its economics are typical of clinical-stage biotech: heavy research and development spending, recurring net losses, and reliance on cash reserves, partnerships, and equity raises to fund operations.

Prime Medicine is pre-revenue and burns tens of millions of dollars per quarter, so the central risks are clinical and financial. As of March 31, 2026 the company reported roughly ~$149.2 million in cash, cash equivalents, investments, and restricted cash, which management expected to fund operations into 2027, implying that another financing will likely be needed and could dilute existing shareholders. Lead programs are still preclinical or just entering the clinic, so a failed readout, a delayed filing, or a safety setback could materially reduce the company's value. It also competes with better-capitalized gene-editing peers, some of which already have approved or later-stage products.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Prime Medicine, Inc.'s investor relations page or your broker.

• Product revenue: None (pre-revenue; collaboration income only)
• Q1 2026 net loss: ~$49.1 million
• Q1 2026 R&D expense: ~$34.1 million
• Cash, equivalents, investments and restricted cash (Mar 31, 2026): ~$149.2 million
• Stated cash runway: Into 2027
• Market capitalization: ~$583 million (approximate, June 2026)

Prime Medicine is not profitable and is not expected to be for years; like most clinical-stage biotechs it is valued on its pipeline and platform rather than current earnings. Its reported cash was guided to fund operations into 2027, which means additional financing is likely before any product could reach the market. Figures are approximate and tied to the asOf date; check the latest filings for current numbers.

There are three common ways to get PRME exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so PRME sits alongside other stocks that express the same thesis.

Walnut takes the basket route. Describe a thesis where PRME fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

If you believe prime editing can become a durable, one-time-treatment platform and that Prime Medicine's narrowed liver franchise will produce convincing early data, the question becomes sizing and overlap with the rest of your portfolio, not timing. This is a binary, pre-revenue story whose value hinges on clinical readouts that are still a year or more away. The risk is that a program stumbles, that the cash runway forces a dilutive raise, or that competing gene-editing approaches reach patients first, any of which could sharply reduce the company's value regardless of the platform's long-term promise.

Whether PRME is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is PRME a buy?, and where the stock could go from here in the PRME stock forecast.

For income investors, whether PRME pays a dividend and how the payout looks is covered in does PRME pay a dividend?